EICHORCondition: Non Small Cell Lung Cancer · Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
This multi-centre phase I dose-escalation study will use a time-to-event continual reassessment method (TIT-CRM). Accrual will start at level 1 (60 Gy in 8 fractions). Patients will be assigned to treatment doses using the TITE-CRM model. The model will use all available information from previously accrued patients to assign the highest dose with a predicted risk of grade 3 toxicity of 30% or less.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| BC Cancer -Vancouver Island | Vancouver, British Columbia, Canada | — |
| London Regional Cancer Program | London, Ontario, Canada | — |
| Sunnybrook Odette Cancer Centre | Toronto, Ontario, Canada | — |
| Princess Margaret Cancer Centre | Toronto, Ontario, Canada | — |
| Centre Hospitalier de l'Universite de Montreal (CHUM) | Montreal, Quebec, Canada | — |
| McGill University Health Centre-Cedars Cancer Centre | Montreal, Quebec, Canada | — |
| Saskatoon Cancer Centre | Saskatoon, Saskatchewan, Canada | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03306680